Ayala Pharmaceuticals, Inc. (ADXS)

OTCMKTS · Delayed Price · Currency is USD

0.0510

+0.0109 (27.18%)

At close: Dec 26, 2025

Ayala Pharmaceuticals Employees

As of December 31, 2023, Ayala Pharmaceuticals had 21 total employees, including 20 full-time and 1 part-time employees.

Employees

21

Change

n/a

Growth

n/a

Revenue / Employee

$619

Profits / Employee

-$2,289,143

Market Cap

2.51M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	21	-	-

Related Stocks

Company Name	Employees
American Oncology Network	1,914
Glass House Brands	374
Silence Therapeutics	116
Elite Pharmaceuticals	68
Northwest Biotherapeutics	25
CytoDyn	13
OpGen	1

Employee Rankings

Ayala Pharmaceuticals News

11 months ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline - Business Wire
11 months ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline - Business Wire
1 year ago - Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - GlobeNewsWire
1 year ago - Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome - GlobeNewsWire
2 years ago - Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Business Wire
2 years ago - Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - Business Wire
2 years ago - Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 - GlobeNewsWire
2 years ago - Ayala Pharmaceuticals Announces Closing of Merger with Biosight - GlobeNewsWire